Clinical Trial Update: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the nivolumab-relatlimab fixed-dose combination versus regorafenib or TAS-102 in patients with later-line metastatic colorectal cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Lonsurf (trifluridine/tipiracil)
• Nivolumab-relatlimab fixed-dose combination (nivolumab-relatlimab)
• Regorafenib (regorafenib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colorectal Neoplasms | Phase 3 | Status: TERMINATED